2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Joseph Alvarnas, MD, the director of Medical Quality at City of Hope National Medical Center, discusses autologous hematopoietic stem cell transplantation (AHCT) for patients with HIV-associated lymphoma.
Joseph Alvarnas, MD, the director of Medical Quality at City of Hope National Medical Center, discusses autologous hematopoietic stem cell transplantation (AHCT) for patients with HIV-associated lymphoma.
A​ recent phase II study compared HIV-associated lymphoma with lymphoma patients without HIV and found that both groups had similar outcomes after AHCT. The one-year survival rate for the HIV-lymphoma patients was 86%.
This research is extremely promising, says Alvarnas, because it was previously believed that those with HIV-associated lymphoma could not undergo transplant safely and were instead treated with minimal chemotherapy or less intense therapies.
Related Content: